Corvus Pharmaceuticals opened lower at $11.20, compared with its previous close of $11.47. In the last trading session, the stock traded between $10.59 and $11.41. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Corvus Pharmaceuticals is now worth
$ 239.80
Giving a profit of
$ 139.80 (139.80%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 3 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.85 (-7.38%)
Day High
$11.41
Day Low
$10.59
Day Open
$11.20
Prev Close
$11.47
Volume
8,03,169
1W Return
0.44%
1M Return
5.90%
3M Return
-27.99%
6M Return
-32.81%
1Y Return
30.02%
Fundamentals
Market Cap ($ Mn)
896
PE Ratio
-
PB Ratio
5.29
PEG Ratio
-
ROE
-25.90%
ROCE
-29.77%
EPS (TTM)
$-0.24
Investment Returns
1 Week
0.44%
1 Month
5.90%
3 Months
-27.99%
6 Months
-32.81%
9 Months
-46.19%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
0.0
Sep 26
Updates
6Nov
Corvus Pharma Q3FY26 Results: Net loss widens to $20.3M on R&D spend
Net loss widened to $20.3 million in Q3FY26 from $10.2 million in Q3FY25. R&D expenses increased to $17.8 million from $8.5 million YoY. Cash reserves stood at $202.9 million as of September 30, 2026. Key data readouts for PTCL and atopic dermatitis expected in 2027.
7 days ago
1Oct
Corvus Pharmaceuticals begins Phase 1b soquelitinib trial for hidradenitis suppurativa
Corvus Pharmaceuticals begins enrollment in Phase 1b trial for hidradenitis suppurativa. Up to 25 patients will receive 200 mg soquelitinib twice daily for 12 weeks. This marks the fourth active clinical indication for soquelitinib. Key efficacy endpoint is HiSCR 50/75 response rate at week 12.
1mo ago
27Aug
Corvus Pharmaceuticals publishes soquelitinib Phase 1 data in Blood journal
Final Phase 1/1b data for soquelitinib published in *Blood* journal. Median overall survival of 28.1 months observed in key patient subgroup. Six complete responses recorded among 24 evaluable patients. No myelosuppression or immunosuppression reported across all doses. Data supports ongoing Phase 3 PTCL trial and planned immune disease studies.
2mo ago
7Aug
Corvus Pharmaceuticals Q2 loss widens to $18M on higher R&D costs
Corvus Pharmaceuticals reported a widened net loss of $18.0 million for Q2 2026, primarily due to increased R&D expenses of $16.0 million for clinical trials. The company maintains strong liquidity with $215.2 million in cash, supporting operations into 2Q28, while advancing its lead candidate soquelitinib in Phase 3 and Phase 2 trials.
3mo ago
9Jun
Corvus invests $5M in Angel Pharma's $13.5M financing
Corvus Pharmaceuticals invested $5 million in Angel Pharmaceuticals' $13.5 million financing round to support clinical development in China. The funding will advance ongoing Phase 1b/2 trials for soquelitinib in atopic dermatitis and a new Phase 2 trial for asthma. Corvus co-founded Angel Pharma in 2020 to facilitate the clinical development and commercialization of its pipeline in China and remains its largest shareholder.
